Anavex Life Sciences Corp. (NASDAQ: AVXL) Securities Fraud Class Action

Anavex Life Sciences Corp. (NASDAQ: AVXL) Securities Fraud Class Action

CompanyAnavex Life Sciences Corp.
CourtUnited States District Court for the Southern District of New York
Case Number1:26-cv-08567
JudgeHonorable Vernon S. Broderick
Class PeriodNovember 26, 2025 through August 28, 2026
Security TypeSecurities


Lead Plaintiff Deadline: November 30, 2026
Days Left to Lead Plaintiff Deadline: 48

The Anavex Life Sciences Corp. securities fraud class action lawsuit was filed on behalf of those who purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex”) (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the “Class Period”). Captioned Kurey v. Anavex Life Sciences Corp., No. 26-cv-08567 (S.D.N.Y.), the Anavex class action lawsuit alleges that Anavex and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your Anavex investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at [email protected]. 

COMPLAINT ALLEGATION SUMMARY:
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Anavex lacked adequate internal controls; (2) the company understated its potential regulatory challenges as a result of misconduct by its former CEO; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID ANAVEX’S STOCK DROP?
On August 28, 2026, the company filed its quarterly financial reports, disclosing that “[f]ollowing the previously disclosed termination of our former CEO in April 2026, management has determined that our disclosure controls and procedures and our internal controls over financial reporting were not effective as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026.” On this news, the price of Anavex’s stock fell more than 6%.

THE LEAD PLAINTIFF PROCESS:
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Anavex securities during the Class Period to seek appointment as lead plaintiff in the Anavex class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.

Complete this form with your transactions in Anavex Life Sciences Corp. securities between November 26, 2025 through August 28, 2026.

Click Here to Print PDF of this Form

    Submit Your Information
    SUBMIT YOUR INFORMATION
    * Denotes required field
    Phone Country code
    Purchase Information
    Sales Information
    Did you purchase shares of Anavex Life Sciences Corp. prior to the Class Period?
    Are you a current or former employee of Anavex Life Sciences Corp.?
    The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. READ MORE
    I agree to the KTMC disclaimer
    I would like to receive new case alerts by email